Supported by National

Natural Science Foundation of China (No. 81000162). Key Word(s): 1. Crohn’s disease; 2. fibroblasts; 3. pathogenesis; Presenting Author: JIE LIANG Additional Authors: KAICHUN WU, DAIMING FAN Corresponding Author: JIE LIANG Affiliations: Xijing Hospital of Digestive Diseases; Xijing Hospital of Digestive DIsease Objective: Inflammatory bowel disease is an important risk factor for colorectal cancer. However, the mechanism of development from IBD to colorectal cancer remains unclear. Methods: SphK2-KO mice and control littermates were used for DSS-induced colitis and AOM-DSS-induced colitis-associated cancer model. Relative index and mechanisms were further investigated. Autophagy activator Results: Sphingosine-1-phosphate

(S1P) produced by upregulation of sphingosine kinase 1 (SphK1) links chronic intestinal inflammation to colitis-associated cancer (CAC) and both are exacerbated by deletion of SphK2. S1P is essential for production of the multifunctional NF-κB-regulated cytokine IL-6, persistent activation of the transcription factor Stat3, and consequent upregulation of the S1P receptor, S1PR1. The pro-drug FTY720 decreased SphK1 and S1PR1 and eliminated the NF-κB-IL-6-Stat3 amplification cascade and development of CAC even in SphK2-/- mice and may be useful in treating colon cancer in individuals EGFR inhibitor drugs with ulcerative colitis. Conclusion: SphK1-S1P-S1PR1 axis is at the nexus between NF-κB and Stat3 and connects chronic inflammation and CAC. Key Word(s): 1. S1P; 2. IBD; 3. Colorectal cancer; 4. STAT3; Presenting Author: SHI HUI Additional Authors: WAN JUN, SU BINBIN Corresponding Author: SHI HUI Affiliations: Nan lou gastrointestinal department 301 hospital; 301 hospital Objective: Many patients with ulcerative colitis (UC) in clinical remission continue to have symptoms of pain and diarrhea despite MCE公司 minimal or no ongoing inflammation. These patients may be considered to have an overlap of UC or Irritable bowel symptoms. The aims of this study were to

prospectively determine the prevalence of Irritable bowel like symptoms in ulcerative colitis patients in remission, and to determine whether IBS-like symptoms correlate with occult inflammation. Methods: We prospectively included 185 patients with UC, who had been in remission for at least 6 months according to laboratory parameters and clinical and endoscopical appearance, 107 with IBS, and 36 healthy controls. Remission was defined by physician assessment: ulcerative colitis disease activity index <3, and serum C-reactive protein <10, while off corticosteroids or biologics. Rome III criteria for IBS. Serum intestinal fatty acid binding protein (I-FABP) and fecal calprotectin (Fc) were measured by ELISA. Results: Of the 185 UC patients, there were 107(57.8%) patients with IBS[69 male, 38 female, mean age (41 ± 17.5)], and 68 patients without IBS[41 male, 27 female, mean age (44 ± 16.2)].